Everhart Financial Group Inc. Has $540,000 Stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Everhart Financial Group Inc. increased its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 72.3% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,285 shares of the company’s stock after buying an additional 539 shares during the period. Everhart Financial Group Inc.’s holdings in IDEXX Laboratories were worth $540,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Hurley Capital LLC acquired a new position in IDEXX Laboratories during the fourth quarter worth $29,000. Rialto Wealth Management LLC acquired a new position in IDEXX Laboratories during the fourth quarter worth $30,000. Colonial Trust Co SC increased its holdings in IDEXX Laboratories by 84.8% during the fourth quarter. Colonial Trust Co SC now owns 85 shares of the company’s stock worth $35,000 after buying an additional 39 shares during the last quarter. Kestra Investment Management LLC acquired a new position in IDEXX Laboratories during the fourth quarter worth $38,000. Finally, Itau Unibanco Holding S.A. increased its holdings in IDEXX Laboratories by 540.0% during the fourth quarter. Itau Unibanco Holding S.A. now owns 96 shares of the company’s stock worth $40,000 after buying an additional 81 shares during the last quarter. 87.84% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, Director M Anne Szostak sold 1,260 shares of the company’s stock in a transaction that occurred on Wednesday, May 21st. The stock was sold at an average price of $512.34, for a total value of $645,548.40. Following the completion of the transaction, the director now owns 1,801 shares of the company’s stock, valued at $922,724.34. This represents a 41.16% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 0.98% of the stock is currently owned by insiders.

IDEXX Laboratories Trading Down 0.8%

Shares of IDEXX Laboratories stock opened at $522.70 on Friday. IDEXX Laboratories, Inc. has a 52-week low of $356.14 and a 52-week high of $530.73. The firm has a 50-day moving average of $473.11 and a 200-day moving average of $444.30. The company has a debt-to-equity ratio of 0.28, a quick ratio of 0.95 and a current ratio of 1.31. The stock has a market cap of $42.04 billion, a PE ratio of 48.99, a PEG ratio of 3.41 and a beta of 1.55.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Thursday, May 1st. The company reported $2.96 earnings per share for the quarter, topping the consensus estimate of $2.93 by $0.03. The business had revenue of $998.43 million during the quarter, compared to analysts’ expectations of $998.25 million. IDEXX Laboratories had a net margin of 22.78% and a return on equity of 55.82%. IDEXX Laboratories’s revenue was up 3.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.71 earnings per share. As a group, sell-side analysts forecast that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

Analysts Set New Price Targets

IDXX has been the topic of several research reports. Wall Street Zen downgraded shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Friday, May 30th. Morgan Stanley upped their price objective on shares of IDEXX Laboratories from $548.00 to $558.00 and gave the company an “overweight” rating in a report on Monday, May 5th. Stifel Nicolaus boosted their target price on shares of IDEXX Laboratories from $460.00 to $510.00 and gave the company a “hold” rating in a research report on Monday, May 19th. Finally, Leerink Partners boosted their target price on shares of IDEXX Laboratories from $515.00 to $580.00 and gave the company an “outperform” rating in a research report on Wednesday. Four research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, IDEXX Laboratories presently has a consensus rating of “Moderate Buy” and an average target price of $546.00.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.